The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
|Articles|March 13, 2012
Dr. Randell Correia Suggests How to Control Costs in Specialty Pharmacy
Randell "RJ" Correia, PharmD, Senior Vice President, Pharmacy Services, Optum Rx, addresses the rapid rise of specialty pharmacy spending. Dr. Correia discusses the possible complications health reform exchanges may cause and the impact they will have on the future of pharmacy benefit drug management.
Advertisement
Randell "RJ" Correia, PharmD, Senior Vice President, Pharmacy Services, Optum Rx, addresses the rapid rise of specialty pharmacy spending. Dr. Correia discusses the possible complications health reform exchanges may cause and the impact they will have on the future of pharmacy benefit drug management.
Advertisement
Related to this article
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.
Advertisement
Advertisement